WIN Consortium

Outstanding international @WIN_Consortium MTB with discussion of difficult cases presented today by @SewantiLimaye of signet cell gastric cancer, adenoid cystic cancer and intrahepatic Cholangiocarcinoma with various driver molecular alterations that may be amenable to targeted therapy combinations including radionuclide therapy @Dr_R_Kurzrock @WIN_Consortium Today’s participants from US, Canada, India, Spain, Australia and China among others.

Great meeting of the @WIN_Consortium Thoracic Cancer Disease Committee to discuss current membership, innovative concepts for thoracic Precision Oncology clinical trials, opportunities for collaborative grant funding and pharmaceutical collaboration @HinaKhanMD @DrRoyHerbstYale @bcarneiro7 @DCarboneMD @NaglaAKarimMD

Expert discussions of potential therapy options for very challenging cases at today’s @WIN_Consortium international MTB including two cases I presented patients with glioma, both IDH WT, one with H3K27M, and both with MDM2 amplification among other drivers, and a case of urothelial cancer. @Dr_R_Kurzrock @SewantiLimaye @JiaJennyLiu @DrSGraff @BrownUCancer @BrownMedicine @BrownUniversity @bcarneiro7 @JerryAzzoli @LiangChengMD @IAbuGheidaMD @BurjeelHoldings @alshamsi2000 @SenduraiMani @VivekSubbiah

Honored to give keynote in session on precision oncology at #BGIICC in Cairo. Hesham ElGhazaly @WIN_Consortium in cancer personalized medicine @Dr_R_Kurzrock Catherine Bresson American Society of Clinical Oncology (@ASCO) linkedin.com/posts/wafike_b…

Enjoyable group dinner event at the National Museum of Egyptian Civilization in Old Cairo during the 18th #BGIICC 2026 meeting. Appreciate time spent with @ASCO leaders including Charles Balch, Lynn Schuchter, and @jrgralow. Great to see Amal Al Omari from King Hussein Cancer Foundation and Center. @WIN_Consortium @OncoDaily linkedin.com/posts/wafike_b…

Great discussions of challenging cases at today’s @WIN_Consortium international MTB including two cases I presented patients with mCRC and either BRAF V600E or KRAS G12C. Helpful discussions given emerging resistance mechanisms in the setting of the BRAF mutation with ARID1A, SMAD4, KRAS, and PIK3CA mutations and for the KRAS G12C options for future therapy beyond sotorasib plus panitumumab being tried for first time at 4 years into the course of the mCRC therapy. The KRAS G12C had previously cleared the liquid biopsies with chemo but continues to be a driver after re-emerging. Dr. Limaye presented a challenging case of EGFR (Exon 19 deletion) and MET-Amplified non TTF1 expressing metastatic lung adenocarcinoma that presented with ovary involvement. The tumor had p53 mutation, CDKN2A/B deletion. Discussion focused on targeting EGFR and MET in her ongoing therapy. @Dr_R_Kurzrock @SewantiLimaye @JiaJennyLiu @DrSGraff @BrownUCancer @BrownMedicine @BrownUniversity @bcarneiro7 @JerryAzzoli @ShiOnaCo @LiangChengMD @IAbuGheidaMD @BurjeelHoldings @alshamsi2000 @SenduraiMani @VivekSubbiah

Honored to meet Her Excellency, Dr. Zainab Shinkafi-Bagudu, @uicc President-Elect of 2024-2026 and a Founder and CEO of the Medicaid Cancer Foundation at the 18th BGIICC in Cairo, Egypt. Looking forward to connecting about opportunities to address equity and access in precision oncology through @WIN_Consortium in cancer personalized medicine Hesham ElGhazaly @oncodaily

Honored to meet HRH. Princess Dina Mired, a global advocate for cancer control at the 18th BGIICC in Cairo. lnkd.in/e388jYMn King Hussein Cancer Foundation and Center Hesham ElGhazaly @WIN_Consortium in cancer personalized medicine @oncodaily

Learning from Dr. Hope Rugo about neoadjuvant therapy approaches and from Dr. Giuseppe Curigliano about CDK4/6 inhibitor resistance in breast cancer at the 18th BGIICC. Thinking about how precision oncology approaches can help accelerate discovery of ways to effectively control the disease. @WIN_Consortium in cancer personalized medicine @oncodaily linkedin.com/posts/wafike_l…

An inspiring opening session at the 18th BGIICC with focus on the challenges of equity in cancer care around the world including in Africa. Panelists spoke about commitments by global societies to achieve much with little. To set the tone, the session started with a video highlighting that “cancer has no borders” and “when she suffers the world suffers.” Past-President of American Society of Clinical Oncology (ASCO) Lynn Schuchter commented on how biosimilars and subcutaneous administration of therapeutic agents such as immunotherapy are reducing costs and reducing barriers to cancer care globally. The spirit of international collaboration is palpable at this meeting and it is an honor to be here representing the @WIN_Consortium in cancer personalized medicine and @BrownMedicine #LegorretaCancerCenter linkedin.com/posts/wafike_l…

Great to meet some giants of oncology this morning at the 18th BGIICC in Cairo, Egypt. @ASCO @myESMO @BurjeelHoldings @WIN_Consortium @jrgralow @curijoey @alshamsi2000 @VivekSubbiah @MDAndersonNews @PennCancer @Dr_R_Kurzrock @oncodaily

Honored to meet with the executive leadership of the Egyptian Cancer Society in Cairo today to discuss strategic collaboration with the @WIN_Consortium ecs.org.eg/about-us/

Outstanding inaugural meeting of the international @WIN_Consortium Rare Cancers Committee chaired by @Dr_R_Kurzrock with a distinguished group of experts and global leaders @SewantiLimaye @JTrentMDPhD @GSholler @targetcancer @RueterJens @LiaTsimberidou @DrTonyLetai @bickythapa02 @AllenChankowsky There are great opportunities for innovative progress with global impact using the latest AI predictive algorithms, technology platforms including tissue and blood-based nucleic acid and other biomarker assays, novel omics, digital pathology, functional precision medicine, consensus guidelines among others. There is much existing data that is low hanging fruit and opportunities for learning from every patient as we try to help every patient. Rare cancers and how they are managed is foundational and eventually will extend to N-of-1 for many other cancers currently thought of as less rare. With the new WIN Consortium Precision Oncology Fellowship, WIN Consortium Disease Committees, discussions with genomics, other omics, AI, patient advocacy groups and pharma companies we are optimistic about progress in the coming years.

Great to see my colleague Dr. Frank Sinicrope @FASinicropeMD at @MayoCancerCare at #GI26 Appreciate Chance to speak about precision oncology and @WIN_Consortium and to hear about ongoing experience with clinical utility of ctDNA.

Great to meet with colleagues Stephen Ford and @Brooke_PhD at @Amgen @AmgenOncology to discuss collaboration on specific therapeutic areas and precision oncology opportunities with @WIN_Consortium @BrownUCancer

Enjoyed speaking with Bruno @Larvol about advances in GI cancer including Claudin18.2, FGFR2, KRAS targeting, and bispecifics that have been discussed so far at #GI26 We also had a nice discussion about precision oncology and @WIN_Consortium @Dr_R_Kurzrock

Great to meet with colleagues at @JazzPharma to discuss our research on ONC201, analogues, and lurbinectedin at #GI26, including collaboration opportunities with @WIN_Consortium

Good conversation at #GI26 with colleagues from @Bayer regarding opportunities in precision oncology and @WIN_Consortium @carisls @ccuris15

Attending the @carisls CARIS Precision Oncology Alliance GI Cancers Working Group meeting this evening in San Francisco with Dr. Safran. Learning about progress in research, technologies and platforms and the impressive evolution of the POA over the last decade. Great to see Drs. @AVanderwalde and @GeorgeSledge51 and to have opportunity to discuss collaboration between @WIN_Consortium and @carisls

Great to see my colleague Dr. Humaid Al Shamsi @alshamsi2000, CEO and Director of the Burjeel Cancer Institute and President of the Emirates Oncology Society at #GI26 @ASCO in San Francisco. @drKMusallam @BurjeelHoldings @WIN_Consortium @drshamsheervp @Dr_R_Kurzrock